AstraZeneca and Amgen said Tezspire (tezepelumab) hit the coprimary endpoints and key secondary endpoints in a Phase 3 study of eosinophilic esophagitis (EoE) in the Crossing trial. The result sets up Tezspire for a potential third indication, aiming to expand beyond asthma and chronic rhinosinusitis with nasal polyps. The Phase 3 win also intensifies competition in EoE, where Sanofi’s Dupixent is the established biologic reference point. With an FDA decision pending after additional steps, the trial data becomes the next catalyst for pricing and formulary positioning in allergy-driven gastroenterology.